Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Expert Review of Anticancer Therapy|July 11, 2022
Immunosenescence, inflammaging, and cancer immunotherapy efficacyJulieta E Rodriguez, Marie Naigeon, Vincent Goldschmidt, et al.
Journal for Immunotherapy of Cancer|April 17, 2024
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumorsRonan Flippot, Marcus Teixeira, Macarena Rey-Cardenas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2025
High circulating IL-6/IL-8 is associated with intratumoral myeloid contexture and poor outcomes in advanced renal cell carcinoma patients treated with PD-1 blockadeLucia Carril-Ajuria, Ronan Flippot, Marie Naigeon, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2024
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 studyLoïc Mourey, Larissa Tames Rainho, Cécile Dalban, et al.
Science Advances|November 8, 2023
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8<sup>+</sup> T cells in patients with advanced NSCLCMarie Naigeon, Matthieu Roulleaux Dugage, François-Xavier Danlos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based ChemotherapyRoberto Ferrara, Marie Naigeon, Edouard Auclin, et al.
Nature Communications|May 3, 2020
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancerClélia Coutzac, Jean-Mehdi Jouniaux, Angelo Paci, et al.
Journal for Immunotherapy of Cancer|May 31, 2022
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 studyLucia Carril-Ajuria, Aude Desnoyer, Maxime Meylan, et al.
Journal of Proteome Research|October 1, 2024
Circulating Proteins Associated with Anti-IL6 Receptor Therapeutic Resistance in the Sera of Patients with Severe COVID-19Jean-Marie Michot, Vito Dozio, Julien Rohmer, et al.
Frontiers in Immunology|November 3, 2023
The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infectionDéborah Lécuyer, Roberta Nardacci, Désirée Tannous, et al.
Pageof 3